AI prescription management raises a familiar healthcare question: efficiency for whom?
A Washington Post opinion piece asks who benefits when AI handles prescriptions. The answer is not automatically patients: the efficiency gains could be real, but so are the risks around accountability, errors, and commercialization.
Prescribing is one of the most sensitive points in the care pathway, which makes it a natural target for automation. AI systems can already help with medication reconciliation, refill triage, formulary checks, and interaction alerts. The promise is obvious: fewer administrative bottlenecks, faster access to needed drugs, and less clerical burden for clinicians.
Yet the central issue raised by this opinion piece is not whether AI can process prescriptions. It is who controls the decision layer. In healthcare, speed often benefits institutions before it benefits patients, especially when automation is deployed to reduce staff workload or increase throughput. That can be good policy — but only if safeguards ensure that exceptions, ambiguity, and patient-specific nuance are not flattened into a machine-generated default.
Prescription systems are also fertile ground for liability confusion. If an AI-generated recommendation leads to harm, responsibility may be diffused across vendors, health systems, pharmacists, and clinicians. That diffusion is not a technical detail; it is a governance problem that can shape whether the technology is trusted at all.
The larger lesson is that AI in medication management should be judged not by the elegance of the software, but by the fairness of the workflow it creates. Efficiency is only progress if it improves access, safety, and accountability at the same time.